Please login to the form below

Not currently logged in
Email:
Password:

Glenn Sblendorio to retire as president of The Medicines Company

He will be replaced as chief financial officer by William O’Connor
Glenn Sblendorio

Glenn Sblendorio is set to retire as president and chief financial officer of New Jersey-based The Medicines Company at the end of March 2016, when he will be succeeded by William O'Connor as chief financial officer.

Sblendorio was appointed as a director at The Medicines Company in July 2011 and has served in his current roles since February 2012.

He has over 20 years of experience in the pharmaceutical industry and prior to joining The Medicines Company held senior managing and financial positions at Eyetech Pharmaceuticals and MPM Capital Advisors.

He currently serves as a director at Amicus Therapeutics, Intercept Pharmaceuticals and Ophthotech Corporation.

He said: “I feel we have accomplished a great deal at The Medicines Company over the last several years, building the portfolio and managing the company through several business challenges.

“I am most proud to be leaving the company with its market cap at an all-time high.”

Sblendorio will also relinquish his seat on the board of directors at the beginning of January but continue as a strategic advisor to Clive Meanwell, current chief executive officer of The Medicines Company, until his retirement in March.

Meanwell said: “Glenn has supported The Medicines Company for more than 14 years and he has been and remains my friend and confidant. I am grateful for the wisdom, patience and perseverance that Glenn has brought to our work together.

“He has played a key role in accumulating so many of the existing products that will help define our future. I thank him for all he has done for the company and wish him well in the future.” 

4th January 2016

From: Sales

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
AMICULUM

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >300 healthcare communications professionals,...

Latest intelligence

Partnering with Patients and Caregivers in Clinical Research
...
Practical advice for Early Scientific Advice (ESA) in HTA submissions
A step-by step guide on the benefits, processes, and key considerations involved in the Healthcare Technology Assessment (HTA) Early Scientific Advice (ESA) consultation as part of planning the holistic evidence...
Jonathan Cooke
The fight against antimicrobial resistance
By Jonathan Cooke...